Provided by Tiger Fintech (Singapore) Pte. Ltd.

X4 Pharmaceuticals Inc

0.3050
-0.0087-2.77%
Volume:2.10M
Turnover:638.61K
Market Cap:52.02M
PE:-3.55
High:0.3218
Open:0.3203
Low:0.2926
Close:0.3137
Loading ...

X4 Pharmaceuticals, Taiba to Distribute Xolremdi in Select Middle East Countries

MT Newswires Live
·
19 Feb

BRIEF-X4 Pharmaceuticals And Taiba Rare Announce Exclusive Agreement For The Distribution And Commercialization Of Xolremdi® (Mavorixafor) In Whim Syndrome In Select Middle East Countries

Reuters
·
19 Feb

X4 Pharmaceuticals and Taiba Rare Announce Exclusive Agreement for the Distribution and Commercialization of Xolremdi® (Mavorixafor) in Whim Syndrome in Select Middle East Countries

THOMSON REUTERS
·
19 Feb

X4 Pharmaceuticals Price Target Maintained With a $1.50/Share by HC Wainwright & Co.

Dow Jones
·
07 Feb

X4 Pharmaceuticals to Cut 30% of Workforce, Close Austria Facility; Shares Fall

MT Newswires Live
·
06 Feb

X4 Pharmaceuticals announces strategic restructuring, reduces headcount by 30%

TIPRANKS
·
06 Feb

X4 Pharmaceuticals Inc - to Reduce Headcount by 43 People, Close Vienna Facility

THOMSON REUTERS
·
06 Feb

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

THOMSON REUTERS
·
06 Feb

X4 Pharmaceuticals Inc - Restructuring Expected to Extend Cash Runway Into H1 2026

THOMSON REUTERS
·
06 Feb

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

GlobeNewswire
·
06 Feb

BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
04 Feb

X4 said to see takeover approach from Italy’s Cheisi, Street Insider reports

TIPRANKS
·
30 Jan

X4 Pharmaceuticals Says Marketing Application for Mavorixafor Validated for Review by EU Regulator

MT Newswires Live
·
24 Jan

BRIEF-X4 Pharmaceuticals Announces EMA Validation Of Marketing Authorization Application

Reuters
·
24 Jan

X4 Pharmaceuticals Inc - Decision on Mavorixafor Maa Expected in 1H 2026

THOMSON REUTERS
·
24 Jan

X4 Pharmaceuticals Announces Ema Validation of Marketing Authorization Application (Maa) for Mavorixafor for the Treatment of Whim Syndrome

THOMSON REUTERS
·
24 Jan